National registry of human embryonic stem cell lines

All human pluripotent or human totipotent stem cell lines derived directly from embryos under the auspices of an institution that is eligible to receive Agency funds must be:

• derived in a manner consistent with the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (TCPS 2) or, before December 9, 2014, the Guidelines for Human Pluripotent Stem Cell Research
• listed in the National Registry
• made available by the researcher to other researchers, subject to reasonable cost-recovery charges

Before June 30, 2010, only human embryonic stem cell lines derived in the course of CIHR-funded projects were required to be listed in the registry.

• No human embryonic stem cell lines have been derived in the course of CIHR-funded projects.
• Investigators with lines derived prior to June 30, 2010 under the auspices of an eligible institution voluntarily listed their cell lines.

Research proposals conducted under the auspices of an institution that is eligible to receive Agency funds using these cell lines need to be reviewed and approved by its Research Ethics Board and the Stem Cell Oversight Committee (SCOC) before the work can commence.

SCOC-approved human embryonic stem cell lines derived under the auspices of Agency-eligible institutions

To date, no decision has been made to disallow a human embryonic stem cell line submitted for SCOC review. Lines that have been disallowed will be listed here.

Date modified:

2024-08-09